First implantable device for hypoxia-mediated angiogenic induction

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Tissue Engineering

Background:

• Delayed or inadequate vascularization is a primary cause of tissue infarction and poor graft survival.
• Current single growth factor delivery methods for vascularization are often ineffective or difficult to control.
• Stimulating physiological angiogenic factor cascades offers a promising alternative approach.

Purpose of the Study:

• To develop and evaluate a novel, practical, and effective implantable device for on-demand delivery of engineered angiogenic signaling.
• To investigate the use of localized cell-generated hypoxia within a collagen material to stimulate angiogenic factor production.
• To assess the in vitro and in vivo efficacy of this angiogenic therapy in promoting vascularization.

Main Methods:

• Human dermal fibroblast-seeded collagen depots were pre-conditioned under cell-generated hypoxia to induce angiogenic factor production (HIF1α, VEGF165).
• The correlation between pre-conditioning duration and retained VEGF165 protein levels was analyzed.
• The angiogenic response was evaluated in vitro using endothelial cell-seeded constructs and in vivo by implanting acellular 3D constructs with angiogenic depots.

Main Results:

• Pre-conditioning duration directly correlated with the level of VEGF165 protein produced and retained within the depots.
• Angiogenic factors released from pre-conditioned depots rapidly induced vascularization in vitro.
• Implanted constructs with angiogenic depots showed significant vessel infiltration and perfusion by 1 week in vivo, unlike non-angiogenic controls.

Conclusions:

• Engineered local cell-hypoxia within collagen materials is an effective strategy for stimulating angiogenic factor cascades.
• This novel implantable device provides on-demand delivery of angiogenic signals, promoting rapid and robust vascularization.
• The stability, tuneability, and cost-effectiveness of this approach make it a promising therapy for improving local tissue perfusion and graft survival.